Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation.
Yazdani-Biuki
Babak
B
Mueller
Thomas
T
Brezinschek
Hans-Peter
HP
Hermann
Josef
J
Graninger
Winfried
W
Wascher
Thomas C
TC
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D000069285:Infliximab; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab